Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements

The immune checkpoint inhibitors (ICTs) emergence has opened up new perspectives in cancer immunotherapy. Nevertheless, serious, including life-threatening conditions caused by ICT cardiotoxic effects pose a number of obstacles to clinical specialists. The lack of knowledge about pathophysiology of...

Full description

Bibliographic Details
Published in:	Рациональная фармакотерапия в кардиологии
Main Authors:	L. D. Khidirova, A. E. Latsvieva, A. V. Vederin
Format:	Article
Language:	English
Published:	Столичная издательская компания 2024-06-01
Subjects:	cardiotoxicity immune checkpoint inhibitors immune-related adverse events myocarditis acute coronary syndrome pericarditis dilated cardiomyopathy takotsubo syndrome arrhythmias
Online Access:	https://www.rpcardio.online/jour/article/view/3022

Similar Items

Immune Checkpoint Inhibitors Related to Cardiotoxicity
by: Ru Chen, et al.
Published: (2022-11-01)

Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials
by: Akash Sharma, et al.
Published: (2024-05-01)

Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy
by: Aya F. Ozaki, et al.
Published: (2025-03-01)

Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
by: Michael Sayer, et al.
Published: (2025-04-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
by: Yu-Wen Zhou, et al.
Published: (2019-11-01)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
by: Roberta Esposito, et al.
Published: (2021-05-01)

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
by: Danielle Delombaerde, et al.
Published: (2023-04-01)

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
by: Harun Muğlu, et al.
Published: (2025-02-01)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
by: María Torrente, et al.
Published: (2022-12-01)

Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors
by: Danielle Delombaerde, et al.
Published: (2024-07-01)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
by: Junyu Chen, et al.
Published: (2022-09-01)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
by: Daniel Ronen, et al.
Published: (2022-03-01)

Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature
by: R. Saad, et al.
Published: (2024-02-01)

Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis
by: Naser Yamani, et al.
Published: (2024-06-01)

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
by: Joshua Longinow, et al.
Published: (2023-02-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database
by: Guojing Yao, et al.
Published: (2025-08-01)

Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
by: Liudmila Zotova
Published: (2023-03-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data
by: D. Delombaerde, et al.
Published: (2025-03-01)

mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort studyResearch in context
by: Phyumar Soe, et al.
Published: (2024-12-01)

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis
by: Ryo Izumi, et al.
Published: (2024-11-01)

The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022
by: Ju-Young Sim, et al.
Published: (2023-04-01)

Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01)

Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis
by: Xi Li, et al.
Published: (2024-06-01)

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
by: Gillian Murtagh, et al.
Published: (2024-02-01)

Peripheral biomarkers to assess risk, severity, and prognosis of immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study
by: Zhengkun Guan, et al.
Published: (2024-10-01)

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
by: V. Quagliariello, et al.
Published: (2024-01-01)

Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review
by: Dong Wang, et al.
Published: (2023-03-01)

Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management
by: Simone Nardin, et al.
Published: (2025-07-01)

Acute Heart Failure in a Young Patient Treated in ICU—Diagnostic Pitfalls
by: Łukasz Surówka, et al.
Published: (2024-09-01)

Treatment efficacy of arrhythmias and dilated cardiomyopathy syndrome of immune-inflammatory nature using plasmapheresis
by: V. A. Kulikova, et al.
Published: (2018-12-01)

Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review
by: Alberto Sánchez-Camacho, et al.
Published: (2025-05-01)

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis
by: Céline Eldani, et al.
Published: (2024-07-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review
by: Demis N. Lipe, et al.
Published: (2024-08-01)

Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
by: Christopher Mann, MD, et al.
Published: (2025-09-01)

Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis
by: Stéphane Ederhy, et al.
Published: (2021-05-01)

Stress Cardiomyopathy (Takotsubo Cardiomyopathy)
by: S. S. Yashin, et al.
Published: (2023-03-01)

Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem
by: A. D. Koltakova, et al.
Published: (2023-10-01)